Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies.

about

Activity of the PI3K-δ,γ inhibitor duvelisib in a phase I trial and preclinical models of T-cell lymphoma.Duvelisib, an oral dual PI3K-δ, γ inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study

P2860

Q49887083-E6854DC8-F4BD-4C93-AF15-A304A492854B Q58697794-04203721-2865-42E7-84AC-DE4F4797B98C

P2860

Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies.

Item

http://www.wikidata.org/entity/Q47388561

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Duvelisib, a novel oral dual i ...... nced hematologic malignancies.

@en

Duvelisib, a novel oral dual i ...... nced hematologic malignancies.

@nl

type

Item

label

Duvelisib, a novel oral dual i ...... nced hematologic malignancies.

@en

Duvelisib, a novel oral dual i ...... nced hematologic malignancies.

@nl

prefLabel

Duvelisib, a novel oral dual i ...... nced hematologic malignancies.

@en

Duvelisib, a novel oral dual i ...... nced hematologic malignancies.

@nl

P1476

Duvelisib, a novel oral dual i ...... nced hematologic malignancies.

@en

P2093

Brad Kahl

http://www.w3.org/2001/XMLSchema#string

Francine F Foss

http://www.w3.org/2001/XMLSchema#string

Ian W Flinn

http://www.w3.org/2001/XMLSchema#string

Jan A Burger

http://www.w3.org/2001/XMLSchema#string

Jeffrey Jones

http://www.w3.org/2001/XMLSchema#string

Jennifer Sweeney

http://www.w3.org/2001/XMLSchema#string

Kerstin Allen

http://www.w3.org/2001/XMLSchema#string

Manish Patel

http://www.w3.org/2001/XMLSchema#string

Mark Douglas

http://www.w3.org/2001/XMLSchema#string

Nitin Jain

http://www.w3.org/2001/XMLSchema#string

P2860

Phosphoinositide 3-kinase delta (PI3Kδ) in leukocyte signaling and function

PI3K in lymphocyte development, differentiation and activation

A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation

Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice

The regulation of IL-10 production by immune cells

The emerging mechanisms of isoform-specific PI3K signalling

Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study

Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.

Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.

Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.

P31

scholarly article

P356

10.1182/BLOOD-2017-05-786566

http://www.w3.org/2001/XMLSchema#string

P407

English

P50

Susan O'Brien

P577

2017-11-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29191916

http://www.w3.org/2001/XMLSchema#string

P932

6033052

http://www.w3.org/2001/XMLSchema#string

Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies.

about

P2860

P2860

Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P407

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P31

P356

P407

P50

P577

P698

P932